Palisade Bio, Inc.
NASDAQ:PALI · NASDAQ Capital Market
+$0.16 today
Vol 3.86M · Avg 3.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-13.0%
avg -152.7%
ROIC
-13.9%
avg -113.2%
ROA
-12.5%
avg -128.6%
Analysis
ROA is currently the strongest return metric at -12.5% versus its period average of -128.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director | $1.01M | — | 68 | $27,353.00 | 0.02% |
Mitchell Lawrence Jones | President & Chief Medical Officer | $704,000.00 | — | 49 | $13,263.00 | <0.01% |
Ryker Willie | Senior Vice President of Finance & Corporate Controller | — | — | — | — | — |
Dawn Louro | VP & Head of Clinical Operations | — | — | — | — | — |
Sharon Skare | Vice President & Global Head of Clinical Operations | — | — | — | — | — |
Joerg Heyer | Head of Translational Science & Medicine | — | — | — | — | — |
Adarsh Patel | Head of Chemistry, Manufacturing & Controls | — | — | — | — | — |
Daniel J. Larkins | Head of Global Regulatory Affairs | — | — | — | $12,160.00 | <0.01% |
Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations | — | — | — | — | — |
James Izanec | VP & Head of Clinical Development | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$17,756.00
Sells
2
$10,298.75
Net Sentiment
+$7,457.25
Net buying
Most Active
Williams Donald Allen
2 transactions
Analysis
Insiders reported 2 buys worth $17,756.00 and 2 sells worth $10,298.75 over the last 12 months. That adds up to net buying of $7,457.25. Williams Donald Allen was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -70.5% | +98.4% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -70.5% over three years. Forward estimates point to Revenue at +98.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Leap Therapeutics, Inc.
LPTX
$31.86M
Athira Pharma, Inc.
ATHA
$26.62M
Daré Bioscience, Inc.
DARE
$20.28M
Rocket One Inc.
HOTH
$13.59M
Entero Therapeutics, Inc.
ENTO
$13.58M
Citius Pharmaceuticals, Inc.
CTXR
$6.17M
BriaCell Therapeutics Corp.
BCTX
$5.43M
Curis, Inc.
CRIS
$5.38M
Processa Pharmaceuticals, Inc.
PCSA
$4.88M
Aspire Biopharma Holdings, Inc.
ASBP
$730,305.00
Who manages PALI?
Palisade Bio, Inc. (PALI) lists 10 active executives. The top listed executive is Ryker Willie, Senior Vice President of Finance & Corporate Controller.
Are PALI insiders buying or selling?
Recent insider activity shows net buying of $646,558.75.
Explore More
Continue the stock analysis
Jump to another research area for this company.